132 related articles for article (PubMed ID: 38309583)
41. I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films.
Poder J; Corde S
Med Phys; 2013 Dec; 40(12):121709. PubMed ID: 24320495
[TBL] [Abstract][Full Text] [Related]
42. AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221.
Thomson RM; Furutani KM; Kaulich TW; Mourtada F; Rivard MJ; Soares CG; Vanneste FM; Melhus CS
Med Phys; 2020 Jun; 47(5):e92-e124. PubMed ID: 31883269
[TBL] [Abstract][Full Text] [Related]
43. Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for (125)I brachytherapy.
Karlsson M; Nilsson J; Lundell M; Carlsson Tedgren A
Brachytherapy; 2014; 13(6):651-6. PubMed ID: 24950821
[TBL] [Abstract][Full Text] [Related]
44. Dosimetric study of the 15 mm ROPES eye plaque.
Granero D; Pérez-Calatayud J; Ballester F; Casal E; de Frutos JM
Med Phys; 2004 Dec; 31(12):3330-6. PubMed ID: 15651616
[TBL] [Abstract][Full Text] [Related]
45. A survey of quality control practices for high dose rate (HDR) and pulsed dose rate (PDR) brachytherapy in the United Kingdom.
Palmer AL; Bidmead M; Nisbet A
J Contemp Brachytherapy; 2012 Dec; 4(4):232-40. PubMed ID: 23378853
[TBL] [Abstract][Full Text] [Related]
46. Retina dose as a predictor for visual acuity loss in
Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R
Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
[TBL] [Abstract][Full Text] [Related]
47. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
48. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.
Zhang H; Martin D; Chiu-Tsao ST; Meigooni A; Thomadsen BR
Brachytherapy; 2010; 9(4):362-72. PubMed ID: 20116342
[TBL] [Abstract][Full Text] [Related]
49. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs.
Rivard MJ; Melhus CS; Sioshansi S; Morr J
Brachytherapy; 2008; 7(4):327-35. PubMed ID: 18782684
[TBL] [Abstract][Full Text] [Related]
50. Hydrogen nanobubbles: A novel approach toward radio-sensitization agents.
Hashemi S; Aghamiri SM; Siavashpour Z; Kahani M; Zaidi H; Jaberi R
Med Phys; 2023 Oct; 50(10):6589-6599. PubMed ID: 37278345
[TBL] [Abstract][Full Text] [Related]
51. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.
Charra-Brunaud C; Harter V; Delannes M; Haie-Meder C; Quetin P; Kerr C; Castelain B; Thomas L; Peiffert D
Radiother Oncol; 2012 Jun; 103(3):305-13. PubMed ID: 22633469
[TBL] [Abstract][Full Text] [Related]
52. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
Johnson JE; Deufel CL; Furutani KM
Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
[TBL] [Abstract][Full Text] [Related]
53. Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5.
Binder C; Mruthyunjaya P; Schefler AC; Seider MI; Crilly R; Hung A; Meltsner S; Mowery Y; Kirsch DG; Teh BS; Jennelle RLS; Studenski MT; Liu W; Lee C; Hayman JA; Kastner B; Hadsell M; Skalet AH
Ocul Oncol Pathol; 2020 May; 6(3):210-218. PubMed ID: 32509767
[TBL] [Abstract][Full Text] [Related]
54.
Jiang P; Purtskhvanidze K; Kandzia G; Neumann D; Luetzen U; Siebert FA; Roider J; Dunst J
Radiat Oncol; 2020 Jul; 15(1):183. PubMed ID: 32727533
[TBL] [Abstract][Full Text] [Related]
55. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy.
Dimopoulos JC; Petrow P; Tanderup K; Petric P; Berger D; Kirisits C; Pedersen EM; van Limbergen E; Haie-Meder C; Pötter R
Radiother Oncol; 2012 Apr; 103(1):113-22. PubMed ID: 22296748
[TBL] [Abstract][Full Text] [Related]
56. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
[TBL] [Abstract][Full Text] [Related]
57. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
[TBL] [Abstract][Full Text] [Related]
58. Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey.
Hrbacek J; Mishra KK; Kacperek A; Dendale R; Nauraye C; Auger M; Herault J; Daftari IK; Trofimov AV; Shih HA; Chen YE; Denker A; Heufelder J; Horwacik T; Swakoń J; Hoehr C; Duzenli C; Pica A; Goudjil F; Mazal A; Thariat J; Weber DC
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):336-343. PubMed ID: 27084651
[TBL] [Abstract][Full Text] [Related]
59. Cervical cancer brachytherapy in Canada: A focus on interstitial brachytherapy utilization.
Taggar AS; Phan T; Traptow L; Banerjee R; Doll CM
Brachytherapy; 2017; 16(1):161-166. PubMed ID: 27914911
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
